"Dose adjustments are probably not required for simultaneous use of GLP1RAs with oral medications
But in the beginning, measure
Based on existing studies, the effects of GLP-1RA on OSA may include weight loss and reduction in glycated hemoglobin
For most patients, reaching goal weight does not signal the end of treatment but rather a transition from the weight loss phase to the weight maintenance phase, which typically requires continued pharmacological support for optimal outcomes as long as benefits outweigh risks
A 36 mg dose of the drug, taken once per day without food and water restrictions, reduced weight by an average of 12.4%, compared to 0.9% for participants in the placebo group
Optional Supportive Services Patients may choose to add supportive therapies, including: Skinny Shots Performance Recovery injections The BVC wellness tracking app Educational, self-guided resources through the BVC Toolkit These optional tools can support energy, metabolism, and consistency while using GLP-1 medication